SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Senti Biosciences Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.23+0.00 (+0.84%)
Close on Oct 19, 2026
- Market cap
- $7.06M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.9232 (−89.45%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Senti Biosciences Holdings, Inc. reported revenue of $22.00K for fiscal 2025. Free cash flow was -$43.64M.
Revenue
$22.00K
FY2025
Operating income
-$54.69M
TTM Q2 2026
Free cash flow
-$43.64M
FY2025
EPS, diluted
-$1.77
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $7.06M
- P/E ratio
- –
- Price to sales
- 321.07
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -617.81%
Fundamentals
- Revenue
- $22.00K
- Net income
- -$49.56M
- EPS, diluted
- -$1.77
- Free cash flow
- -$43.64M
- Book value per share
- -$0.11
- Diluted shares
- 31M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$54.69M
Net income
-$49.56M
EPS, diluted
-$1.77
Free cash flow
–
Reported periodTrailing twelve months